Knight Therapeutics Inc
TSX:GUD
Intrinsic Value
Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. [ Read More ]
The intrinsic value of one GUD stock under the Base Case scenario is 4.81 CAD. Compared to the current market price of 5.79 CAD, Knight Therapeutics Inc is Overvalued by 17%.
Valuation Backtest
Knight Therapeutics Inc
Run backtest to discover the historical profit from buying and selling GUD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Knight Therapeutics Inc
| Current Assets | 365.1m |
| Cash & Short-Term Investments | 157.8m |
| Receivables | 110.3m |
| Other Current Assets | 97m |
| Non-Current Assets | 580.4m |
| Long-Term Investments | 116.4m |
| PP&E | 17.9m |
| Intangibles | 369.8m |
| Other Non-Current Assets | 76.4m |
| Current Liabilities | 114m |
| Accounts Payable | 85.4m |
| Other Current Liabilities | 28.7m |
| Non-Current Liabilities | 84.6m |
| Long-Term Debt | 49.5m |
| Other Non-Current Liabilities | 35.1m |
Earnings Waterfall
Knight Therapeutics Inc
|
Revenue
|
328.2m
CAD
|
|
Cost of Revenue
|
-175.5m
CAD
|
|
Gross Profit
|
152.7m
CAD
|
|
Operating Expenses
|
-146.3m
CAD
|
|
Operating Income
|
6.4m
CAD
|
|
Other Expenses
|
-23.2m
CAD
|
|
Net Income
|
-16.8m
CAD
|
Free Cash Flow Analysis
Knight Therapeutics Inc
What is Free Cash Flow?
GUD Profitability Score
Profitability Due Diligence
Knight Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Knight Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
GUD Solvency Score
Solvency Due Diligence
Knight Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Knight Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GUD Price Targets Summary
Knight Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for GUD is 6.77 CAD with a low forecast of 5.3 CAD and a high forecast of 7.98 CAD.
Shareholder Return
GUD Price
Knight Therapeutics Inc
| Average Annual Return | -6.58% |
| Standard Deviation of Annual Returns | 15.77% |
| Max Drawdown | -50% |
| Market Capitalization | 585.8m CAD |
| Shares Outstanding | 101 170 382 |
| Percentage of Shares Shorted | 2.52% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec and currently employs 660 full-time employees. The company went IPO on 2014-02-28. The firm's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. The company owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.
Contact
IPO
Employees
Officers
The intrinsic value of one GUD stock under the Base Case scenario is 4.81 CAD.
Compared to the current market price of 5.79 CAD, Knight Therapeutics Inc is Overvalued by 17%.
You don't have any saved screeners yet
